This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

1018 ISS

Dynavax Technologies Corporation

Drug Names(s): ISS-1018

Description: Dynavax Technologies is developing short, immunostimulatory DNA sequences (ISS). 1018 ISS is a CpG oligodeoxynucleotides (CpG-ODNs). CpG-ODNs affect innate and adaptive immune responses, including antigen presentation, costimulatory molecule expression, dendritic cell maturation, and induction of cytokines enhancing antibody-dependent cell-mediated cytotoxicity (ADCC).

1018 ISS News

Pink Sheet Novel Biologics In US Might Not Start Getting Suffixes Until August

Pink Sheet Will Dynavax’ HBV Vaccine Resubmission Make The Safety Grade?

Pink Sheet Dynavax Hepatitis B Vaccine Could Get Comparative Post-Market Autoimmunity Assessment

Pink Sheet Heplisav’s Hopes For U.S. Approval Could Rest On Narrower Population

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug